147 related articles for article (PubMed ID: 24761212)
41. A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.
Tantai N; Chaikledkaew U; Tanwandee T; Werayingyong P; Teerawattananon Y
BMC Health Serv Res; 2014 Apr; 14():170. PubMed ID: 24731689
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of embryo transfer strategies: a decision analytic model using long-term costs and consequences of singletons and multiples born as a consequence of IVF.
van Heesch MM; van Asselt AD; Evers JL; van der Hoeven MA; Dumoulin JC; van Beijsterveldt CE; Bonsel GJ; Dykgraaf RH; van Goudoever JB; Koopman-Esseboom C; Nelen WL; Steiner K; Tamminga P; Tonch N; Torrance HL; Dirksen CD
Hum Reprod; 2016 Nov; 31(11):2527-2540. PubMed ID: 27907897
[TBL] [Abstract][Full Text] [Related]
43. Preliminary results of consolidation chemotherapy following concurrent chemoradiation after radical surgery in high-risk early-stage carcinoma of the uterine cervix.
Lee JW; Kim BG; Lee SJ; Lee SH; Park CS; Lee JH; Huh SJ; Bae DS
Clin Oncol (R Coll Radiol); 2005 Sep; 17(6):412-7. PubMed ID: 16149283
[TBL] [Abstract][Full Text] [Related]
44. Feasibility and effectiveness of postoperative adjuvant concurrent chemoradiation therapy in Japanese patients with high-risk early-stage cancer of the uterine cervix.
Shibata K; Kajiyama H; Terauchi M; Yamamoto E; Ino K; Nawa A; Kikkawa F
Int J Clin Oncol; 2008 Jun; 13(3):233-8. PubMed ID: 18553233
[TBL] [Abstract][Full Text] [Related]
45. Completion hysterectomy after chemoradiotherapy for locally advanced adeno-type cervical carcinoma: updated survival outcomes and experience in post radiation surgery.
Yang J; Yang J; Cao D; Shen K; Ma J; Zhang F
J Gynecol Oncol; 2020 Mar; 31(2):e16. PubMed ID: 31912674
[TBL] [Abstract][Full Text] [Related]
46. Postoperative adjuvant chemotherapy combined with intracavitary brachytherapy achieved the equivalent survival compared with concurrent chemoradiotherapy in cervical cancer patients with intermediate-risk.
Yu H; Zhang L; Li D; Liu N; Yin Y; Zhang L; Yuan L; Liu M; Sheng X
Jpn J Clin Oncol; 2019 Aug; 49(8):714-718. PubMed ID: 31329905
[TBL] [Abstract][Full Text] [Related]
47. The upper limit of optimal tumor size in patients with FIGO 2018 stage IB2 cervical cancer undergoing radical hysterectomy.
Hwang WY; Kim JH; Suh DH; Kim K; No JH; Kim YB
Int J Gynecol Cancer; 2020 Jul; 30(7):975-980. PubMed ID: 32467336
[TBL] [Abstract][Full Text] [Related]
48. Radical Hysterectomy Plus Concurrent Chemoradiation/Radiation Therapy Is Negatively Associated With Return to Work in Patients With Cervical Cancer.
Nakamura K; Masuyama H; Ida N; Haruma T; Kusumoto T; Seki N; Hiramatsu Y
Int J Gynecol Cancer; 2017 Jan; 27(1):117-122. PubMed ID: 27668396
[TBL] [Abstract][Full Text] [Related]
49. Cervical cancer: combined modality therapy.
Grigsby PW
Cancer J; 2001; 7 Suppl 1():S47-50. PubMed ID: 11504285
[TBL] [Abstract][Full Text] [Related]
50. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
Chongqing T; Liubao P; Xiaohui Z; Jianhe L; Xiaomin W; Gannong C; Siying W; Lihui O; Ziying Z
Pharmacoeconomics; 2014 Mar; 32(3):235-43. PubMed ID: 23709451
[TBL] [Abstract][Full Text] [Related]
51. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
[No Abstract] [Full Text] [Related]
53. Cost-effectiveness of radical hysterectomy with adjuvant radiotherapy versus radical radiotherapy for FIGO stage IIB cervical cancer.
Chai Y; Wang J; Wang T; Shi F; Wang J; Su J; Yang Y; Zhou X; Ma H; He B; Liu Z
Onco Targets Ther; 2016; 9():349-54. PubMed ID: 26855584
[TBL] [Abstract][Full Text] [Related]
54. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.
Hall PS; McCabe C; Stein RC; Cameron D
J Natl Cancer Inst; 2012 Jan; 104(1):56-66. PubMed ID: 22138097
[TBL] [Abstract][Full Text] [Related]
55. A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy.
Retèl VP; van der Molen L; Hilgers FJ; Rasch CR; L'Ortye AA; Steuten LM; van Harten WH
BMC Cancer; 2011 Nov; 11():475. PubMed ID: 22051143
[TBL] [Abstract][Full Text] [Related]
56. Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors.
Kim YB; Cho JH; Keum KC; Lee CG; Seong J; Suh CO; Kim GE
Gynecol Oncol; 2007 Jan; 104(1):58-63. PubMed ID: 16919718
[TBL] [Abstract][Full Text] [Related]
57. Long-term results of early adjuvant concurrent chemoradiotherapy for high-risk, early stage uterine cervical cancer patients after radical hysterectomy.
Kim SW; Chun M; Ryu HS; Chang SJ; Kong TW; Oh YT; Kang SH
BMC Cancer; 2017 Apr; 17(1):297. PubMed ID: 28454573
[TBL] [Abstract][Full Text] [Related]
58. [Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy].
Ma R; Zhang H; Zou L; Qu Y
Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):125-30. PubMed ID: 25877610
[TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F
Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495
[TBL] [Abstract][Full Text] [Related]
60. Survival and prognostic factors comparing stage IB 1 versus stage IB 2 cervical cancer treated with primary radical hysterectomy.
Srisomboon J; Kietpeerakool C; Suprasert P; Manopanya M; Siriaree S; Charoenkwan K; Cheewakriangkrai C; Sae-Teng C
Asian Pac J Cancer Prev; 2011; 12(7):1753-6. PubMed ID: 22126559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
